Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR

Am J Physiol Gastrointest Liver Physiol. 2005 Mar;288(3):G447-56. doi: 10.1152/ajpgi.00209.2004. Epub 2004 Oct 14.

Abstract

Colorectal cancer is a leading cause of cancer-related morbidity and mortality in the United States. Curcumin, the yellow pigment in turmeric, possesses inhibitory effects on growth of a variety of tumor cells by reducing cell proliferation and inducing apoptosis. Effects of the peroxisome proliferator-activated receptor-gamma (PPARgamma) on stimulating cell differentiation and on inducing cell cycle arrest have attracted attention from the perspective of treatment and prevention of cancer. The aim of this study was to elucidate the mechanisms by which curcumin inhibits colon cancer cell growth. In the present report, we observed that curcumin, in a dose-dependent manner, inhibited the growth of Moser cells, a human colon cancer-derived cell line, and stimulated the trans-activating activity of PPARgamma. Further studies demonstrated that activation of PPARgamma was required for curcumin to inhibit Moser cell growth. Activation of PPARgamma mediated curcumin suppression of the expression of cyclin D1, a critical protein in the cell cycle, in Moser cells. In addition, curcumin blocked EGF signaling by inhibiting EGF receptor (EGFR) tyrosine phosphorylation and suppressing the gene expression of EGFR mediated by activation of PPARgamma. In addition to curcumin reduction of the level of phosphorylated PPARgamma, inhibition of cyclin D1 expression played a major and significant role in curcumin stimulation of PPARgamma activity in Moser cells. Taken together, our results demonstrated for the first time that curcumin activation of PPARgamma inhibited Moser cell growth and mediated the suppression of the gene expression of cyclin D1 and EGFR. These results provided a novel insight into the roles and mechanisms of curcumin in inhibition of colon cancer cell growth and potential therapeutic strategies for treatment of colon cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Colonic Neoplasms / pathology
  • Curcumin / pharmacology*
  • Cyclin D1 / biosynthesis*
  • ErbB Receptors / biosynthesis*
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
  • Gene Expression / drug effects*
  • Humans
  • Immunoprecipitation
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • L-Lactate Dehydrogenase / metabolism
  • PPAR gamma / agonists*
  • PPAR gamma / genetics
  • Phosphorylation / drug effects
  • Plasmids / genetics
  • RNA / biosynthesis
  • RNA / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transfection
  • Tyrosine / metabolism

Substances

  • Antineoplastic Agents
  • PPAR gamma
  • Cyclin D1
  • Tyrosine
  • RNA
  • L-Lactate Dehydrogenase
  • ErbB Receptors
  • Extracellular Signal-Regulated MAP Kinases
  • JNK Mitogen-Activated Protein Kinases
  • Curcumin